Soltamox (Tamoxifen Citrate) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Soltamox

Breast Cancer Clinical Trials »

What Is a Clinical Trial?

A clinical trial is a research program conducted with patients to evaluate a new medical treatment, drug or device. The purpose of a breast cancer clinical trial is to find new and improved methods of treating the disease. Clinical trials make it possible to apply the latest scientific and technological advances to patient care.

During a breast cancer clinical trial, researchers, usually physicians, use the best available treatment as a standard to evaluate new treatments. These treatments may be a new drug, surgery or an alternative medicine.

First, researchers study new treatment options in the laboratory in test tubes and animals. If those results are promising, new treatments are further evaluated in a small group of people, and, finally, in a larger clinical trial.

When a new medical treatment is studied for the first time in humans, no one knows exactly how it will work. With any new treatment, there are possible risks as well as be...

Read the Breast Cancer Clinical Trials article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Soltamox

Breast Cancer Slideshow Pictures

Take the Breast Cancer Quiz

Disease Prevention in Women Slideshow Pictures

font size

OVERDOSE

Signs observed at the highest doses following studies to determine LD₅₀ in animals were respiratory difficulties and convulsions.

Acute overdosage in humans has not been reported. In a study of advanced metastatic cancer patients which specifically determined the maximum tolerated dose of tamoxifen in evaluating the use of very high doses to reverse multidrug resistance, acute neurotoxicity manifested by tremor, hyperreflexia, unsteady gait and dizziness were noted. These symptoms occurred within 3-5 days of beginning tamoxifen and cleared within 2-5 days after stopping therapy. No permanent neurologic toxicity was noted. One patient experienced a seizure several days after tamoxifen was discontinued and neurotoxic symptoms had resolved. The causal relationship of the seizure to tamoxifen therapy is unknown. Doses given in these patients were all greater than 400 mg/m² loading dose, followed by maintenance doses of 150 mg/m² of tamoxifen given twice a day.

In the same study, prolongation of the QT interval on the electrocardiogram was noted when patients were given doses higher than 250 mg/m² loading dose, followed by maintenance doses of 80 mg/m² of tamoxifen given twice a day. For a woman with a body surface area of 1.5 m² the minimal loading dose and maintenance doses given at which neurological symptoms and QT changes occurred were at least 6 fold higher in respect to the maximum recommended dose.

No specific treatment for overdosage is known; treatment must be symptomatic.

CONTRAINDICATIONS

Tamoxifen citrate is contraindicated in patients with known hypersensitivity to the drug or any of its ingredients.

Reduction in Breast Cancer Incidence in High Risk Women and Women with DCIS Tamoxifen is contraindicated in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus.

Last reviewed on RxList: 11/24/2008
This monograph has been modified to include the generic and brand name in many instances.